Deciphering the mechanism behind Fibroblast Growth Factor (FGF) induced biphasic signal-response profiles

Cell Communication and Signaling

Volumn 12, Issue 1, 2014, Pages

  Kanodia, Jitendra ^a   Chai, Diana ^a   Vollmer, Jannik ^a   Kim, Jaeyeon ^a   Raue, Andreas ^a   Finn, Greg ^a   Schoeberl, Birgit ^a  

^a MERRIMACK PHARMACEUTICALS   (United States)

Author keywords

Biphasic response; FGF signaling pathway; High throughput quantification; HSGAGs; ODE modeling; Particle swarm optimization

Indexed keywords

ADAPTOR PROTEIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; HEPARAN SULFATE; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; RAS PROTEIN;

ALGORITHM; ARTICLE; BIPHASIC SIGNAL RESPONSE; CELLULAR PARAMETERS; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DYNAMICS; H1703 CELL LINE; IN VITRO STUDY; LIGAND BINDING; LUNG CANCER CELL LINE; MOLECULAR INTERACTION; PARTICLE SWARM OPTIMIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; VALIDATION PROCESS; BIOLOGICAL MODEL; HUMAN; METABOLISM; TUMOR CELL LINE;

CELL LINE, TUMOR; FIBROBLAST GROWTH FACTORS; HUMANS; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL;

EID: 84901696140     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/1478-811X-12-34     Document Type: Article

References (50)

1. Peptide growth factors are multifunctional. Sporn MB, Roberts AB, Nature 1988 332 217 219 10.1038/332217a0 2831460 (Pubitemid 18076650)
2. Some recent advances in the chemistry and biology of transforming growth factor-beta. Sporn MB, Roberts AB, Wakefield LM, de Crombrugghe B, J Cell Biol 1987 105 1039 1045 10.1083/jcb.105.3.1039 3308901 (Pubitemid 18029829)
3. Characterisation of the second messenger pathway underlying neurite outgrowth stimulated by FGF. Williams EJ, Furness J, Walsh FS, Doherty P, Development 1994 120 1685 1693 8050374 (Pubitemid 24175909)
4. Ligand concentration is a driver of divergent signaling and pleiotropic cellular responses to FGF. Garcia-Maya M, Anderson AA, Kendal CE, Kenny AV, Edwards-Ingram LC, Holladay A, Saffell JL, J Cell Physiol 2006 206 386 393 10.1002/jcp.20483 16155940 (Pubitemid 43062807)
5. Fibroblast growth factor-2 stimulation of p42/44MAPK phosphorylation and IkappaB degradation is regulated by heparan sulfate/heparin in rat mammary fibroblasts. Delehedde M, Seve M, Sergeant N, Wartelle I, Lyon M, Rudland PS, Fernig DG, J Biol Chem 2000 275 33905 33910 10.1074/jbc.M005949200 10944532
6. Enhancement of fibroblast growth factor (FGF) activity by an FGF-binding protein. Tassi E, Al-Attar A, Aigner A, Swift MR, McDonnell K, Karavanov A, Wellstein A, J Biol Chem 2001 276 40247 40253 11509569
7. Proteoglycans: master regulators of molecular encounter? Lander AD, Matrix Biol 1998 17 465 472 10.1016/S0945-053X(98)90093-2 9881597 (Pubitemid 28566880)
8. The heparin-binding (fibroblast) growth factor family of proteins. Burgess WH, Maciag T, Annu Rev Biochem 1989 58 575 606 10.1146/annurev.bi.58. 070189.003043 2549857 (Pubitemid 19172981)
9. Cell-surface glycosaminoglycans. Höök M, Kjellén L, Johansson S, Annu Rev Biochem 1984 53 847 869 10.1146/annurev.bi.53.070184. 004215 6433783 (Pubitemid 14059152)
10. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Dieci MV, Arnedos M, Andre F, Soria JC, Cancer Discov 2013 3 264 279 10.1158/2159-8290.CD-12-0362 23418312
11. Using computational modeling to drive the development of targeted therapeutics. Nielsen UB, Schoeberl B, IDrugs 2005 8 822 826 16254802 (Pubitemid 41479279)
12. The FGF family: biology, pathophysiology and therapy. Beenken A, Mohammadi M, Nat Rev Drug Discov 2009 8 235 253 10.1038/nrd2792 19247306
13. Comparative expression of fibroblast growth factor mRNAs in benign and malignant breast disease. Anandappa SY, Winstanley JH, Leinster S, Green B, Rudland PS, Barraclough R, Br J Cancer 1994 69 772 776 10.1038/bjc.1994.146 7511406 (Pubitemid 24112704)
14. Direct binding of integrin alphavbeta3 to FGF1 plays a role in FGF1 signaling. Mori S, Wu C-Y, Yamaji S, Saegusa J, Shi B, Ma Z, Kuwabara Y, Lam KS, Isseroff RR, Takada YK, Takada Y, J Biol Chem 2008 283 18066 18075 10.1074/jbc.M801213200 18441324
15. Measurement and modeling of signaling at the single-cell level. Kolitz SE, Lauffenburger D a, Biochemistry 2012 51 7433 7443 10.1021/bi300846p 22954137
16. New insights into receptor regulation. Poste G, J Appl Physiol 1984 57 1297 1305 6151557
17. Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Schoeberl B, Eichler-Jonsson C, Gilles ED, Müller G, Nat Biotechnol 2002 20 370 375 10.1038/nbt0402-370 11923843 (Pubitemid 34286330)
18. Insulin-like growth factor-I receptor signal transduction and the Janus Kinase/Signal Transducer and Activator of Transcription (JAK-STAT) pathway. Himpe E, Kooijman R, Biofactors 2008 35 76 81
19. The heparan sulfate co-receptor and the concentration of fibroblast growth factor-2 independently elicit different signalling patterns from the fibroblast growth factor receptor. Zhu H, Duchesne L, Rudland PS, Fernig DG, Cell Commun Signal 2010 8 14 10.1186/1478-811X-8-14 20576134
20. Fibroblast growth factor 2 induced proliferation in osteoblasts and bone marrow stromal cells: a whole cell model. Dupree M a, Pollack SR, Levine EM, Laurencin CT, Biophys J 2006 91 3097 3112 10.1529/biophysj.106.087098 16861274 (Pubitemid 44526499)
21. Potentiation and inhibition of bFGF binding by heparin: a model for regulation of cellular response. Fannon M, Forsten KE, Nugent M a, Biochemistry 2000 39 1434 1445 10.1021/bi991895z 10684625 (Pubitemid 30090713)
22. A reaction-diffusion model of basic fibroblast growth factor interactions with cell surface receptors. Filion RJ, Popel AS, Ann Biomed Eng 2004 32 645 663 15171620
23. Ligand-induced coupling versus receptor pre-association: cellular automaton simulations of FGF-2 binding. Gopalakrishnan M, Forsten-Williams K, Täuber UC, J Theor Biol 2004 227 239 251 10.1016/j.jtbi.2003.11.004 14990388 (Pubitemid 38281154)
24. Potential mechanisms for the regulation of growth factor binding by heparin. Forsten KE, Fannon M, Nugent M a, J Theor Biol 2000 205 215 230 10.1006/jtbi.2000.2064 10873433 (Pubitemid 30662921)
25. Model analysis of difference between EGF pathway and FGF pathway. Yamada S, Taketomi T, Yoshimura A, Biochem Biophys Res Commun 2004 314 1113 1120 10.1016/j.bbrc.2004.01.009 14751248 (Pubitemid 38142398)
26. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT, Cancer Res 2010 70 6704 6714 10.1158/0008-5472.CAN-10-0460 20643779
27. High-dimensional Bayesian parameter estimation: case study for a model of JAK2/STAT5 signaling. Hug S, Raue A, Hasenauer J, Bachmann J, Klingmüller U, Timmer J, Theis FJ, Math Biosci 2013 246 293 304 10.1016/j.mbs.2013.04.002 23602931
28. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDermott LA, Coldren CD, Nemenoff RA, Merrick DT, Helfrich BA, Bunn PA, Heasley LE, Mol Pharmacol 2009 75 196 207 10.1124/mol.108.049544 18849352
29. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, Linhardt RJ, Mohammadi M, Mol Cell 2000 6 743 750 10.1016/S1097-2765(00)00073-3 11030354
30. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Pellegrini L, Burke DF, von Delft F, Mulloy B, Blundell TL, Nature 2000 407 1029 1034 10.1038/35039551 11069186
31. Kinetics of basic fibroblast growth factor binding to its receptor and heparan sulfate proteoglycan: a mechanism for cooperactivity. Nugent MA, Edelman ER, Biochemistry 1992 31 8876 8883 10.1021/bi00152a026 1390674
32. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly. Ibrahimi OA, Zhang F, Hrstka SCL, Mohammadi M, Linhardt RJ, Biochemistry 2004 43 4724 4730 10.1021/bi0352320 15096041 (Pubitemid 38509093)
33. EGFR and FGFR signaling through FRS2 is subject to negative feedback control by ERK1/2. Wu Y, Chen Z, Ullrich A, Biol Chem 2003 384 1215 1226 12974390 (Pubitemid 37121193)
34. The kinetics of FGF-2 binding to heparan sulfate proteoglycans and MAP kinase signaling. Forsten-Williams K, Chua CC, Nugent MA, J Theor Biol 2005 233 483 499 10.1016/j.jtbi.2004.10.020 15748910 (Pubitemid 40320595)
35. A new optimizer using particle swarm theory. Eberhart R, Kennedy J, MHS'95 Proc Sixth Int Symp Micro Mach Hum Sci 1995 39 43
36. Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood. Raue A, Kreutz C, Maiwald T, Bachmann J, Schilling M, Klingmüller U, Timmer J, Bioinformatics 2009 25 1923 1929 10.1093/bioinformatics/btp358 19505944
37. Cooperative heparin-mediated oligomerization of fibroblast growth factor-1 (FGF1) precedes recruitment of FGFR2 to ternary complexes. Brown A, Robinson CJ, Gallagher JT, Blundell TL, Biophys J 2013 104 1720 1730 10.1016/j.bpj.2013.02.051 23601319
38. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jané-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P, De Silva M, et al. Nature 2012 483 603 607 10.1038/nature11003 22460905
39. Highly sulfated nonreducing end-derived heparan sulfate domains bind fibroblast growth factor-2 with high affinity and are enriched in biologically active fractions. Naimy H, Buczek-Thomas JA, Nugent M, Leymarie N, Zaia J, J Biol Chem 2011 286 19311 19319 10.1074/jbc.M110.204693 21471211
40. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Rapraeger A, Krufka A, Olwin BB, Science 1991 252 (80-) 1705 1708 1646484 (Pubitemid 21917092)
41. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM, Cell 1991 64 841 848 10.1016/0092-8674(91)90512-W 1847668 (Pubitemid 121001170)
42. Heparin-dependent binding and autophosphorylation of epidermal growth factor (EGF) receptor by heparin-binding EGF-like growth factor but not by EGF. Aviezer D, Yayon A, Proc Natl Acad Sci U S A 1994 91 12173 12177 10.1073/pnas.91.25.12173 7991602 (Pubitemid 24368627)
43. Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors. Tessler S, Rockwell P, Hicklin D, Cohen T, Levi BZ, Witte L, Lemischka IR, Neufeld G, J Biol Chem 1994 269 12456 12461 8175651 (Pubitemid 24202025)
44. Sulfated oligosaccharides promote hepatocyte growth factor association and govern its mitogenic activity. Zioncheck TF, Richardson L, Liu J, Chang L, King KL, Bennett GL, Fügedi P, Chamow SM, Schwall RH, Stack RJ, J Biol Chem 1995 270 16871 16878 10.1074/jbc.270.28.16871 7622503
45. Glycosaminoglycans can modulate extracellular localization of the wingless protein and promote signal transduction. Reichsman F, Smith L, Cumberledge S, J Cell Biol 1996 135 819 827 10.1083/jcb.135.3.819 8909553 (Pubitemid 26372935)
46. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Ruppert R, Hoffmann E, Sebald W, Eur J Biochem 1996 237 295 302 10.1111/j.1432-1033.1996.0295n.x 8620887 (Pubitemid 26110301)
47. Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. Takada T, Katagiri T, Ifuku M, Morimura N, Kobayashi M, Hasegawa K, Ogamo A, Kamijo R, J Biol Chem 2003 278 43229 43235 10.1074/jbc.M300937200 12912996 (Pubitemid 37345942)
48. Heparan sulfate acts as a bone morphogenetic protein coreceptor by facilitating ligand-induced receptor hetero-oligomerization. Kuo W, Digman MA, Lander AD, Mol Biol Cell 2010 21 4028 4041 10.1091/mbc.E10-04-0348 20861306
49. Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Fon Tacer K, Bookout AL, Ding X, Kurosu H, John GB, Wang L, Goetz R, Mohammadi M, Kuro-o M, Mangelsdorf DJ, Kliewer SA, Mol Endocrinol 2010 24 2050 2064 10.1210/me.2010-0142 20667984
50. An Adaptive Metropolis Algorithm. Haario H, Saksman E, Tamminen J, Bernoulli 2001 7 223 242 10.2307/3318737 (Pubitemid 33793059)